ORION CORPORATION STOCK EXCHANGE RELEASE 4 JULY 2014 at 09.30 EEST
150,000 Orion A-shares converted into B-shares
In accordance with Section 3 of the Articles of Association of Orion Corporation, 150,000 A-shares have been converted into 150,000 B-shares. The conversion has been entered into the Trade Register on 4 July 2014.
The total number of shares in Orion Corporation is 141,257,828 which, after the conversion, consists of 41,372,816 A-shares and 99,885,012 B-shares.
| Olli Huotari
SVP, Corporate Functions
|| Jari Karlson
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2013 amounted to EUR 1,007 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Orion Oyj via Globenewswire